Systematic Literature Review on the Incidence of Herpes Zoster in Populations at Increased Risk of Disease in the EU/EEA, Switzerland, and the UK.
Herpes zoster
High-risk populations
Incidence
Shingles
Systematic review
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
received:
04
01
2024
accepted:
15
03
2024
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
24
4
2024
Statut:
aheadofprint
Résumé
Older adults and patients with underlying conditions such as immunocompromised (IC) populations (e.g., due to medical conditions or immunosuppressive medication) are at increased risk for herpes zoster (HZ). The first HZ recombinant vaccine for IC patients was approved in 2020. Limited evidence exists to inform decision-makers on HZ incidence in high-risk patients in Europe. This systematic literature review (SLR) assessed HZ incidence across 14 high-risk populations in the European Union/European Economic Area, Switzerland, and the United Kingdom. An SLR (Embase, Medline, 2002-2022, observational studies) was performed to identify HZ incidence (i.e., primary outcomes: rate or cumulative; secondary: relative incidence) in type 1 and 2 diabetes mellitus (DM); chronic obstructive pulmonary disease and asthma; depression; rheumatic disorders (RD); multiple sclerosis (MS); inflammatory bowel diseases (IBD); psoriasis; lupus; human immunodeficiency virus (HIV); solid organ transplantation (SOT); solid organ malignancy (SOM); hematologic malignancy (HM); and stem cell transplantation (SCT). Of 776 unique records screened, 59 studies were included (24 reported incidence rate per 1000 person-years; two, cumulative incidence per 1000 persons; and 33, relative incidence). The highest incidence rates were reported for SOT (12.1-78.8) and SCT (37.2-56.1); HM (2.9-32.0); RD (0.41-21.5); lupus (11.0-16.5); IC mixed population (11.3-15.5); HIV/AIDS (11.8-13.0); chronic respiratory diseases (4.7-11.4); SOM (8.8-11.0); IBD (7.0-10.8); DM (4.3-9.4); depression (7.2-7.6); MS (5.7-6.3); and psoriasis (5.3-6.1). In many high-risk populations, HZ incidence was higher for older age groups, women, and some treatments. The HZ incidence rate in Europe increased with age and varied across high-risk populations, with high rates for solid organ and stem cell transplants, cancer, and rheumatoid arthritis. Most studies were retrospective with methodological differences affecting generalizability and comparability. Future studies should stratify data by IC population, age, sex, severity, medication, and study timeframe.
Identifiants
pubmed: 38656653
doi: 10.1007/s40121-024-00963-w
pii: 10.1007/s40121-024-00963-w
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. GSK.
Références
Werner RN, Nikkels AF, Marinović B, et al. European consensus-based (S2k) guideline on the management of herpes zoster – guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV), part 1: diagnosis. J Eur Acad Dermatol Venereol. 2017;31(1):9–19. https://doi.org/10.1111/jdv.13995 .
doi: 10.1111/jdv.13995
pubmed: 27804172
McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125–34. https://doi.org/10.1093/cid/ciz1090 .
doi: 10.1093/cid/ciz1090
pubmed: 31677266
Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. J Infect Dis. 2021;224(12 Suppl 2):S429–42. https://doi.org/10.1093/infdis/jiab387 .
doi: 10.1093/infdis/jiab387
pubmed: 34590136
pmcid: 8482024
Parikh R, Singer D, Chmielewski-Yee E, Dessart C. Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence. Hum Vaccin Immunother. 2023;19(3):2263979. https://doi.org/10.1080/21645515.2023.2263979 .
doi: 10.1080/21645515.2023.2263979
pubmed: 37967254
pmcid: 10653743
Volpi A, Boccalini S, Dari S, et al. The potential public health impact of herpes zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16(2):327–34. https://doi.org/10.1080/21645515.2019.1657753 .
doi: 10.1080/21645515.2019.1657753
pubmed: 31442095
European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=-1 . Accessed Oct 10 2022.
CDC. Shingles overview. https://www.cdc.gov/shingles/about/index.html . Accessed Sept 10 2022.
Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170. https://doi.org/10.1186/1471-2334-13-170 .
doi: 10.1186/1471-2334-13-170
pubmed: 23574765
pmcid: 3637114
Curran D, Callegaro A, Fahrbach K, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389–403. https://doi.org/10.1007/s40121-021-00567-8 .
doi: 10.1007/s40121-021-00567-8
pubmed: 34874546
Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):1–7.
doi: 10.1186/s12877-017-0420-9
Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):192. https://doi.org/10.3390/v14020192 .
doi: 10.3390/v14020192
pubmed: 35215786
pmcid: 8876683
Bardach AE, Palermo C, Alconada T, et al. Herpes zoster epidemiology in Latin America: a systematic review and meta-analysis. PLoS ONE. 2021;16(8): e0255877. https://doi.org/10.1371/journal.pone.0255877 .
doi: 10.1371/journal.pone.0255877
pubmed: 34383851
pmcid: 8360515
Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157(1):30–54. https://doi.org/10.1097/j.pain.0000000000000307 .
doi: 10.1097/j.pain.0000000000000307
pubmed: 26218719
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6): e004833. https://doi.org/10.1136/bmjopen-2014-004833 .
doi: 10.1136/bmjopen-2014-004833
pubmed: 24916088
pmcid: 4067812
Bricout H, Haugh M, Olatunde O, Prieto RG. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health. 2015;15:466. https://doi.org/10.1186/s12889-015-1753-y .
doi: 10.1186/s12889-015-1753-y
pubmed: 25940080
pmcid: 4435558
van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714–32.
doi: 10.1080/21645515.2020.1847582
pubmed: 33651654
pmcid: 8115759
Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions v6.3. https://training.cochrane.org/handbook/current . Accessed Apr 19 2023.
Preferred reporting items for systematic reviews and meta-analyses (PRISMA). http://prisma-statement.org/ . Accessed Apr 19 2023.
European Centre for Disease Prevention and Control (ECDC). https://ecdc.europa.eu/en/home . Accessed Oct 4 2022.
European Commission (EC). https://ec.europa.eu/commission/index_en . Accessed Oct 4 2022.
EuroSurveillance. https://www.eurosurveillance.org/ . Accessed Oct 4 2022.
World Health Organization (WHO). https://www.who.int/ . Accessed Oct 4 2022.
EuroStat. https://ec.europa.eu/eurostat . Accessed Oct 4 2022.
United Nations Statistics Division. https://unstats.un.org/home/ . Accessed Oct 4 2022.
Barraco F, Greil R, Herbrecht R, et al. Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis. Br J Haematol. 2020;191(5):764–74. https://doi.org/10.1111/bjh.16729 .
doi: 10.1111/bjh.16729
pubmed: 32583458
Batram M, Witte J, Schwarz M, et al. Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007–2018. Dermatol Ther (Heidelb). 2021;11(3):1009–26. https://doi.org/10.1007/s13555-021-00535-7 .
doi: 10.1007/s13555-021-00535-7
pubmed: 33959878
Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75. https://doi.org/10.1186/s12931-018-0742-y .
doi: 10.1186/s12931-018-0742-y
pubmed: 29699563
pmcid: 5921395
Bollaerts K, Alexandridou M, Verstraeten T. Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in England. Vaccine X. 2019;1: 100007. https://doi.org/10.1016/j.jvacx.2019.100007 .
doi: 10.1016/j.jvacx.2019.100007
pubmed: 31384729
pmcid: 6668231
Esteban-Vasallo MD, Domínguez-Berjón MF, Gil-Prieto R, Astray-Mochales J, Gil de Miguel A. Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain). Hum Vaccin Immunother. 2014;10(6):1650–60. https://doi.org/10.4161/hv.28620 .
doi: 10.4161/hv.28620
pubmed: 24805130
pmcid: 5396250
Fernández-Ruiz M, Origüen J, Lora D, et al. Herpes zoster in kidney transplant recipients: protective effect of anti-cytomegalovirus prophylaxis and natural killer cell count: a single-center cohort study. Transpl Int. 2018;31(2):187–97. https://doi.org/10.1111/tri.13076 .
doi: 10.1111/tri.13076
pubmed: 28940695
Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for rheumatology biologics register. Ann Rheum Dis. 2013;72(2):229–34. https://doi.org/10.1136/annrheumdis-2011-201108 .
doi: 10.1136/annrheumdis-2011-201108
pubmed: 22532633
Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015;60(8):1269–77. https://doi.org/10.1093/cid/ciu1161 .
doi: 10.1093/cid/ciu1161
pubmed: 25601456
Jansen K, Haastert B, Michalik C, et al. Incidence and risk factors of herpes zoster among HIV-positive patients in the German competence network for HIV/AIDS (KompNet): a cohort study analysis. BMC Infect Dis. 2013;13:372. https://doi.org/10.1186/1471-2334-13-372 .
doi: 10.1186/1471-2334-13-372
pubmed: 23937603
pmcid: 3751196
Kho MML, Roest S, Bovée DM, et al. Herpes zoster in solid organ transplantation: incidence and risk factors. Front Immunol. 2021;12: 645718. https://doi.org/10.3389/fimmu.2021.645718 .
doi: 10.3389/fimmu.2021.645718
pubmed: 33815403
pmcid: 8012754
Muñoz-Quiles C, López-Lacort M, Ampudia-Blasco FJ, Díez-Domingo J. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009–2014. Hum Vaccin Immunother. 2017;13(11):2606–11. https://doi.org/10.1080/21645515.2017.1368600 .
doi: 10.1080/21645515.2017.1368600
pubmed: 28933622
pmcid: 5798425
Muñoz-Quiles C, López-Lacort M, Díez-Domingo J. Risk and impact of herpes zoster among COPD patients: a population-based study, 2009–2014. BMC Infect Dis. 2018;18(1):203. https://doi.org/10.1186/s12879-018-3121-x .
doi: 10.1186/s12879-018-3121-x
pubmed: 29724175
pmcid: 5934818
Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, Orrico-Sánchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014. BMC Infect Dis. 2020;20(1):905. https://doi.org/10.1186/s12879-020-05648-6 .
doi: 10.1186/s12879-020-05648-6
pubmed: 33256624
pmcid: 7708196
Pavlopoulou ID, Poulopoulou S, Melexopoulou C, Papazaharia I, Zavos G, Boletis IN. Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis. BMC Infect Dis. 2015;15:285. https://doi.org/10.1186/s12879-015-1038-1 .
doi: 10.1186/s12879-015-1038-1
pubmed: 26204926
pmcid: 4513398
Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2021;81(1):41–7. https://doi.org/10.1136/annrheumdis-2021-220651 .
doi: 10.1136/annrheumdis-2021-220651
pubmed: 34321218
Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. Rheumatology (UK). 2018;57(6):997–1001. https://doi.org/10.1093/rheumatology/key023 .
doi: 10.1093/rheumatology/key023
Schröder C, Enders D, Schink T, Riedel O. Incidence of herpes zoster amongst adults varies by severity of immunosuppression. J Infect. 2017;75(3):207–15. https://doi.org/10.1016/j.jinf.2017.06.010 .
doi: 10.1016/j.jinf.2017.06.010
pubmed: 28676411
Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431–8. https://doi.org/10.1002/art.23112 .
doi: 10.1002/art.23112
pubmed: 18050184
Steingrímsson V, Gíslason GK, Þorsteinsdóttir S, et al. A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. Eur J Haematol. 2021;106(3):346–53. https://doi.org/10.1111/ejh.13553 .
doi: 10.1111/ejh.13553
pubmed: 33211356
Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44. https://doi.org/10.1001/jama.2009.146 .
doi: 10.1001/jama.2009.146
pubmed: 19224750
Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726–35. https://doi.org/10.1016/j.jid.2018.01.039 .
doi: 10.1016/j.jid.2018.01.039
pubmed: 29505759
pmcid: 6083876
Thomas K, Lazarini A, Kaltsonoudis E, et al. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology (UK). 2021;60(5):2223–30. https://doi.org/10.1093/rheumatology/keaa557 .
doi: 10.1093/rheumatology/keaa557
van Besouw NM, van Hal PT, Zuijderwijk JM, et al. Herpes zoster after lung transplantation boosts varicella zoster virus-specific adaptive immune responses. J Heart Lung Transplant. 2016;35(12):1435–42. https://doi.org/10.1016/j.healun.2016.04.009 .
doi: 10.1016/j.healun.2016.04.009
pubmed: 27293105
Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000–2012. BMJ Open. 2018;8(6): e020528. https://doi.org/10.1136/bmjopen-2017-020528 .
doi: 10.1136/bmjopen-2017-020528
pubmed: 29880565
pmcid: 6009512
Aldaz P, Díaz JA, Loayssa JR, Dronda MJ, Oscáriz M, Castilla J. Herpes zoster incidence in diabetic patients. An Sist Sanit Navar. 2013;36(1):57–62. https://doi.org/10.4321/s1137-66272013000100006 .
doi: 10.4321/s1137-66272013000100006
pubmed: 23648493
Calabria S, Ronconi G, Dondi L, et al. Patterns of prescription, hospitalizations and costs of herpes zoster in patients at risk, from a large Italian claims database. Glob Reg Health Technol Assess. 2020;7(1):66–71. https://doi.org/10.33393/grhta.2020.2026 .
doi: 10.33393/grhta.2020.2026
pubmed: 36627965
pmcid: 9677609
Baronaite Hansen R, Jacobsen S. Infections increase risk of arterial and venous thromboses in Danish patients with systemic lupus erythematosus: 5102 patient-years of follow up. J Rheumatol. 2014;41(9):1817–22. https://doi.org/10.3899/jrheum.131399 .
doi: 10.3899/jrheum.131399
pubmed: 25128505
Biemans VB, Sleutjes JA, De Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther. 2020;51(9):880–8.
doi: 10.1111/apt.15689
pubmed: 32237087
pmcid: 7187329
Blaizot R, Ouattara E, Fauconneau A, Beylot-Barry M, Pham-Ledard A. Infectious events and associated risk factors in mycosis fungoides/Sézary syndrome: a retrospective cohort study. Br J Dermatol. 2018;179(6):1322–8. https://doi.org/10.1111/bjd.17073 .
doi: 10.1111/bjd.17073
pubmed: 30098016
Blennow O, Fjaertoft G, Winiarski J, Ljungman P, Mattsson J, Remberger M. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis–the incidence remains high. Biol Blood Marrow Transplant. 2014;20(10):1646–9. https://doi.org/10.1016/j.bbmt.2014.06.002 .
doi: 10.1016/j.bbmt.2014.06.002
pubmed: 24914821
Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15(1):35–42.
doi: 10.1093/ecco-jcc/jjaa145
pubmed: 32969471
Danhof S, Strifler S, Hose D, et al. Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy. J Cancer Res Clin Oncol. 2019;145(3):561–71. https://doi.org/10.1007/s00432-018-2807-1 .
doi: 10.1007/s00432-018-2807-1
pubmed: 30519736
Daudén E, Carretero G, Rivera R, et al. Long-term safety of nine systemic medications for psoriasis: a cohort study using the Spanish registry of adverse events for biological therapy in dermatological diseases (BIOBADADERM) registry. J Am Acad Dermatol. 2020;83(1):139–50. https://doi.org/10.1016/j.jaad.2020.03.033 .
doi: 10.1016/j.jaad.2020.03.033
pubmed: 32213306
Dogliotti I, Ragaini S, Vassallo F, et al. Real life use of bendamustine in elderly patients with lymphoid neoplasia. J Pers Med. 2021;11(4):249. https://doi.org/10.3390/jpm11040249 .
doi: 10.3390/jpm11040249
pubmed: 33808164
pmcid: 8066290
Favalli EG, Desiati F, Atzeni F, et al. Serious infections during anti-TNFα treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8(3):266–73. https://doi.org/10.1016/j.autrev.2008.11.002 .
doi: 10.1016/j.autrev.2008.11.002
pubmed: 19022409
Formicone F, Fargnoli MC, Pisani F, Rascente M, Famulari A, Peris K. Cutaneous manifestations in Italian kidney transplant recipients. Transplant Proc. 2005;37(6):2527–8. https://doi.org/10.1016/j.transproceed.2005.06.067 .
doi: 10.1016/j.transproceed.2005.06.067
pubmed: 16182734
Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis. 2009;28(4):331–7. https://doi.org/10.1007/s10096-008-0628-x .
doi: 10.1007/s10096-008-0628-x
pubmed: 18797940
Heider U, Rademacher J, Kaiser M, Kleeberg L, Von Metzler I, Sezer O. Decrease in CD4+ T-Cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2010;10(2):134–7. https://doi.org/10.3816/CLML.2010.n.019 .
doi: 10.3816/CLML.2010.n.019
Hellgren J, Risedal A, Källén K. Rituximab in multiple sclerosis at general hospital level. Acta Neurol Scand. 2020;141(6):491–9. https://doi.org/10.1111/ane.13225 .
doi: 10.1111/ane.13225
pubmed: 31990978
Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation: incidence, risk factors, and complications. Liver Transpl. 2004;10(9):1140–3. https://doi.org/10.1002/lt.20219 .
doi: 10.1002/lt.20219
pubmed: 15350004
Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020;14(10):1385–93.
doi: 10.1093/ecco-jcc/jjaa075
pubmed: 32280965
Kaden J, Völp A, Wesslau C. High graft protection and low incidences of infections, malignancies and other adverse effects with intra-operative high dose ATG-induction: a single centre cohort study of 760 cases. Ann Transplant. 2013;18:9–22. https://doi.org/10.12659/aot.883792 .
doi: 10.12659/aot.883792
pubmed: 23792496
Kamber C, Zimmerli S, Suter-Riniker F, et al. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients. Bone Marrow Transplant. 2015;50(4):573–8. https://doi.org/10.1038/bmt.2014.290 .
doi: 10.1038/bmt.2014.290
pubmed: 25599166
Lenti MV, Levison S, Eliadou E, et al. A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: the cross Pennine study. Dig Liver Dis. 2018;50(12):1299–304. https://doi.org/10.1016/j.dld.2018.07.007 .
doi: 10.1016/j.dld.2018.07.007
pubmed: 30077465
Leon L, Peñuelas M, Candel FJ, et al. Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting. Ther Adv Musculoskelet Dis. 2019. https://doi.org/10.1177/1759720X19878004 .
doi: 10.1177/1759720X19878004
pubmed: 31636721
pmcid: 6783660
Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients: a French retrospective study of 238 patients. Leukemia. 2003;17(1):45–51. https://doi.org/10.1038/sj.leu.2402784 .
doi: 10.1038/sj.leu.2402784
pubmed: 12529659
Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology. 2006;71(3–4):164–7. https://doi.org/10.1159/000106065 .
doi: 10.1159/000106065
pubmed: 17641534
Obrișcă B, Vornicu A, Jurubiță R, et al. Corticosteroids are the major contributors to the risk for serious infections in autoimmune disorders with severe renal involvement. Clin Rheumatol. 2021;40(8):3285–97. https://doi.org/10.1007/s10067-021-05646-2 .
doi: 10.1007/s10067-021-05646-2
pubmed: 33595739
Pour L, Adam Z, Buresova L, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9(2):151–3. https://doi.org/10.3816/CLM.2009.n.036 .
doi: 10.3816/CLM.2009.n.036
pubmed: 19406726
Rampotas A, Djebbari F, Panitsas F, et al. Efficacy and tolerability of VCD chemotherapy in a UK real-world dataset of elderly transplant-ineligible newly diagnosed myeloma patients. Eur J Haematol. 2021;106(4):563–73. https://doi.org/10.1111/ejh.13588 .
doi: 10.1111/ejh.13588
pubmed: 33496996
Rodriguez-Moreno A, Sanchez-Fructuoso AI, Calvo N, et al. Varicella infection in adult renal allograft recipients: experience at one center. Transplant Proc. 2006;38(8):2416–8. https://doi.org/10.1016/j.transproceed.2006.08.060 .
doi: 10.1016/j.transproceed.2006.08.060
pubmed: 17097954
Sulowicz J, Wojas-Pelc A, Kuzniewski M, Ignacak E, Janda K, Sulowicz W. Cutaneous viral infections in patients after kidney transplantation: risk factors. Polskie Arch Med Wewnetrznej. 2013;123(12):686–92. https://doi.org/10.20452/pamw.2013 .
doi: 10.20452/pamw.2013
Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35(11):1065–9. https://doi.org/10.1038/sj.bmt.1704959 .
doi: 10.1038/sj.bmt.1704959
pubmed: 15806119
Tischer J, Engel N, Fritsch S, et al. Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Ann Hematol. 2015;94(10):1677–88. https://doi.org/10.1007/s00277-015-2423-y .
doi: 10.1007/s00277-015-2423-y
pubmed: 26055139
Van Den Neste E, Michaux L, Layios N, et al. High incidence of complications after 2-chloro-2’-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83(6):356–63. https://doi.org/10.1007/s00277-004-0858-7 .
doi: 10.1007/s00277-004-0858-7
pubmed: 15024607
van der Have M, Belderbos TDG, Fidder HH, et al. Screening prior to biological therapy in Crohn’s disease: Adherence to guidelines and prevalence of infections—results from a multicentre retrospective study. Dig Liver Dis. 2014;46(10):881–6. https://doi.org/10.1016/j.dld.2014.07.006 .
doi: 10.1016/j.dld.2014.07.006
pubmed: 25081843
Zappulo E, Buonomo AR, Saccà F, et al. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect Dis. 2019;6(11):1–9. https://doi.org/10.1093/ofid/ofz445 .
doi: 10.1093/ofid/ofz445
Nissen JC, Hummel M, Brade J, et al. The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage: a single center experience. BMC Infect Dis. 2014;14(1):364. https://doi.org/10.1186/1471-2334-14-364 .
doi: 10.1186/1471-2334-14-364
pubmed: 24992940
pmcid: 4227097
Lair-Mehiri L, Stefanescu C, Vaysse T, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis. 2020;52(3):268–73.
doi: 10.1016/j.dld.2019.10.003
pubmed: 31732444